The ongoing clinical trial HERES NCT 05,170,256 is evaluating trastuzumab (an anti-HER2 monoclonal antibody) and standard treatment with chemo- and immunotherapy as a first-line treatment for HER2-positive ESCC patients. The gene discussed is ERBB2; the disease is esophageal squamous cell carcinoma.